Clinical Trials Directory

Trials / Conditions / Advanced Hematologic Malignancies

Advanced Hematologic Malignancies

7 registered clinical trials studyying Advanced Hematologic Malignancies — 3 currently recruiting.

StatusTrialSponsorPhase
RecruitingHow [14C]-DSP-5336 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Patients Wi
NCT07444268
Sumitomo Pharma America, Inc.Phase 1
RecruitingA Clinical Trial Evaluating TQB2101 in Subjects With Advanced Hematologic Malignancies
NCT07113925
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Phase 1
TerminatedThe Safety and Efficacy of Multiple-dose of WJ01024 in Subject With Advanced Cancer
NCT04991129
Suzhou Junjing BioSciences Co., Ltd.Phase 1
RecruitingReduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft
NCT05088356
Stanford UniversityPhase 1
CompletedOral Histone Deacetylase Inhibitor 4SC-202 in Patients With Advanced Hematologic Malignancies (TOPAS)
NCT01344707
4SC AGPhase 1
CompletedStudy to Evaluate Safety, Tolerability, Maximum Tolerated Dose (MTD), Efficacy, and Pharmacokinetics (PKs) of
NCT01034475
Wake Forest University Health SciencesPhase 1
CompletedClofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies
NCT00943592
University of ChicagoPhase 1 / Phase 2